Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which IV drug tames severe preeclampsia better? labetalol vs hydralazine

NCT ID NCT07572656

Disease control Sponsor: Muhammad Aamir Latif Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study compared two intravenous blood pressure medications, labetalol and hydralazine, in 132 pregnant women with severe preeclampsia. The goal was to see which drug more effectively lowered blood pressure to safe levels. Results could help doctors in the local setting choose the best treatment for this serious condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
labetalol and hydralazine (intravenous blood pressure medications)
What this could lead to
If one drug works better, it could help doctors choose the most effective treatment for severe preeclampsia in this population.
What could go wrong
This is a small, single-center study with no blinding, so results may not apply broadly. Both drugs are already in use, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

132 people

The number who actually took part.

Started

May 2024

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant women * Both primiparous and multiparous women * Aged 20-35 years * Gestational age ≥20weeks (assessed on last menstrual period) * With severe preeclampsia Exclusion Criteria: * Known allergy to hydralazine or labetalol * Deranged liver function tests due to any other cause * Women with pre-existing hypertension systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥80 mmHg * Patients receiving more than one antihypertensive drug since admission * Women with chronic renal failure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Preeclampsia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

preeclampsia severe pre-eclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Preeclampsia

Contacts and locations

Locations

  • Sadiq Abbasi Hospital

    Bahawalpur, Punjab Province, 63100, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.